Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 2, 2010, Pages 176-184

  Gorai, Itsuo ^a   Tanaka, Yaku ^a   Hattori, Shin ^a   Iwaoki, Yasuhisa ^b  

^a International University of Health and Welfare   (Japan)

^b JA Yoshida General Hospital   (Japan)

Author keywords

Adherence; Compliance; Osteoporosis; Persistence; Postmenopausal women

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; RALOXIFENE; 1-HYDROXYCHOLECALCIFEROL; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; HYDROXYCOLECALCIFEROL;

ADULT; AGED; ALOPECIA AREATA; ANGINA PECTORIS; ARTICLE; BONE DENSITY; CLINICAL TRIAL; COLON DIVERTICULOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAPHORESIS; DIZZINESS; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GALLSTONE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HYPERCALCIURIA; JAPANESE; KNEE PAIN; LEG CRAMP; LEG EDEMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MYALGIA; NAUSEA; OSTEOPENIA; PARESTHESIA; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH PAIN; SWEATING; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; BLOOD; BONE; BONE DEVELOPMENT; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; JAPAN; METABOLIC BONE DISEASE; MIDDLE AGED; OSTEOLYSIS; PATIENT; QUESTIONNAIRE; STATISTICS; TIME; URINE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE RESORPTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; JAPAN; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT DROPOUTS; QUESTIONNAIRES; RALOXIFENE; STATISTICS AS TOPIC; TIME FACTORS;

EID: 77952484046     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0112-4     Document Type: Article

References (23)

1. Tosteson ANA, Grove MR, Hammond CS et al (2003) Early discontinuation of treatment for osteoporosis. Am J Inn Med 115:209-216
2. Eastell R, Garnero P, Vrijens B et al (2003) Influence of patient compliance with residronate therapy on bone turnover marker and bone mineral density response: the IMPACT study. Calcif Tissue Int 72:P297
3. Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporosis Int 14:965-968
4. Caro JJ, Ishak KJ, Huybrechits KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003-1008
5. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis Int 18:1023-1031
6. Gorai I, Chaki O, Taguchi Y et al (1999) Early postmenopausal bone loss is prevented by estrogen and partially by 1-alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1-alpha-OH-vitamin D3. Calcif Tissue Int 65:16-22
7. O'Donnell S, Moher D, Thomas K et al (2008) Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab 26:531-542
8. Ringe JD, Farahmand P, Schacht E, Rozehnal A (2007) Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 27:425-434
9. Lekkerkerker F, Kanis JA, Alsayed N et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporosis Int 18:1311-1317
10. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331-337
11. Slemenda CW, Longcope CL, Peacock M, Hui SL, Johnston CC (1996) Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri- and postmenopausal women. J Clin Invest 97:14-21
12. Gorai I, Chaki O, Nakayama M, Minaguchi H (1995) Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int 57:100-104
13. Blackburn GF, Shah HP, Kenten JH, Leland R, Kamin RA, Kink J, Peterman J, Powell MJ, Shah A, Talley DB, Tyagi SK, Wilkins E, Wu T-G, Massey RJ (1991) Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnosis. Clin Chem 37:1534-1539
14. Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694-702
15. Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117-1123
16. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497
17. Siris E, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
18. Zanchetta JR, Hakim C, Lombas C (2004) Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis. Curr Ther Res Clin Exp 65:470-480
19. Rossini M, Bianchi G, Munno ODi et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis Int 17:914-921
20. Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporosis Int 15:1003-1008
21. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
22. Bouxsein ML, Delmas PD (2008) Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 23:1155-1167
23. Reginster J-Y, Collette J, Nerprez A et al (2008) Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42:832-836